These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21699947)

  • 1. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark.
    Andrews N; Stowe J; Miller E; Svanström H; Johansen K; Bonhoeffer J; Hviid A;
    Vaccine; 2012 Apr; 30(19):3042-6. PubMed ID: 21699947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.
    Mantadakis E; Farmaki E; Buchanan GR
    J Pediatr; 2010 Apr; 156(4):623-8. PubMed ID: 20097358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella].
    Autret E; Jonville-Béra AP; Galy-Eyraud C; Hessel L
    Therapie; 1996; 51(6):677-80. PubMed ID: 9164004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward better vaccine safety data and safer vaccination.
    Braun MM
    Pediatrics; 2008 Mar; 121(3):625-6. PubMed ID: 18310214
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
    Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
    Yadav S; Thukral R; Chakarvarti A
    Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection.
    Olesen AB; Juul S; Thestrup-Pedersen K
    Acta Derm Venereol; 2003; 83(6):445-50. PubMed ID: 14690341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
    Mrozek-Budzyn D; Kiełtyka A; Majewska R
    Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
    Pareek M; Pattison HM
    Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of measles-containing vaccines in 1-year-old children.
    Klein NP; Lewis E; Fireman B; Hambidge SJ; Naleway A; Nelson JC; Belongia EA; Yih WK; Nordin JD; Hechter RC; Weintraub E; Baxter R
    Pediatrics; 2015 Feb; 135(2):e321-9. PubMed ID: 25560438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia.
    Uno Y; Uchiyama T; Kurosawa M; Aleksic B; Ozaki N
    Vaccine; 2012 Jun; 30(28):4292-8. PubMed ID: 22521285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [So dangerous are not measles, mumps and rubella...A qualitative survey of causes of MMR vaccination refusal in the county of Vejle].
    Gerdes J; Thorsen T
    Ugeskr Laeger; 2006 Aug; 168(33):2670-4. PubMed ID: 16942688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage.
    Gold M; Dugdale S; Woodman RJ; McCaul KA
    Vaccine; 2010 Jun; 28(26):4308-11. PubMed ID: 20430123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.
    Barlow WE; Davis RL; Glasser JW; Rhodes PH; Thompson RS; Mullooly JP; Black SB; Shinefield HR; Ward JI; Marcy SM; DeStefano F; Chen RT; Immanuel V; Pearson JA; Vadheim CM; Rebolledo V; Christakis D; Benson PJ; Lewis N;
    N Engl J Med; 2001 Aug; 345(9):656-61. PubMed ID: 11547719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the French national health insurance information system as a tool in vaccine safety assessment: application to febrile convulsions after pediatric measles/mumps/rubella immunization.
    Hanf M; Quantin C; Farrington P; Benzenine E; Hocine NM; Velten M; Tubert-Bitter P; Escolano S
    Vaccine; 2013 Dec; 31(49):5856-62. PubMed ID: 24135575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.